Intravitreal Pegaptanib
PreclinicalSmall molecule
Intravitreal Pegaptanib is one of 16 small molecule programs targeting Myopia. It is currently in Preclinical.
1
Indications
1
Total Trials
0
Active Trials
15
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
20 competitors in Myopia
#DrugCompanyPhaseTrials
1Atropen
FFresenius Kabi Taiwan Ltd.
Approved
Alphagan
NovartisApproved
Mitosol
UUroGen Pharma Ltd.
Approved
Isopto Carpine
AAdvanz Pharma
Approved
Oxylone
AbbVieApproved
Mydriacyl
FFalcon
Approved
Lotemax
PPharmos
Approved
Atropine Sulfate
FFresenius Kabi USA, LLC
Phase 3
OT-101
OOncotelic Inc.
Phase 3
Eylea
RegeneronPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Myopia1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Intravitreal Pegaptanib. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- LL.V. Prasad Eye Institute